GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $143,456.40 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 2,154 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40. Following the completion of the sale, the chief executive officer now directly owns 105,426 shares of the company’s stock, valued at approximately $7,021,371.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, September 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87.

GeneDx Price Performance

WGS opened at $77.74 on Friday. The company has a fifty day moving average price of $47.44 and a two-hundred day moving average price of $33.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.22 and a current ratio of 2.40. GeneDx Holdings Corp. has a 52 week low of $1.16 and a 52 week high of $89.11. The firm has a market capitalization of $2.09 billion, a PE ratio of -25.00 and a beta of 2.32.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million during the quarter, compared to analyst estimates of $64.98 million. During the same quarter in the previous year, the business earned ($0.82) EPS. The firm’s revenue was up 44.3% on a year-over-year basis. As a group, analysts anticipate that GeneDx Holdings Corp. will post -0.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on WGS. TD Cowen raised their price target on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Wells Fargo & Company raised their price target on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday. The Goldman Sachs Group raised their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday. Craig Hallum lifted their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, BTIG Research lifted their target price on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and an average target price of $59.33.

Hedge Funds Weigh In On GeneDx

Institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of GeneDx in the 2nd quarter valued at $34,000. nVerses Capital LLC acquired a new position in shares of GeneDx in the 2nd quarter valued at $50,000. CWM LLC acquired a new position in shares of GeneDx in the 3rd quarter valued at $89,000. SG Americas Securities LLC acquired a new position in shares of GeneDx in the 3rd quarter valued at $198,000. Finally, Thompson Davis & CO. Inc. lifted its position in GeneDx by 20.8% in the 1st quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock valued at $220,000 after acquiring an additional 4,150 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.